REVIEW

Lorcaserin: Making headway

Cynthia Gershome

Cynthia Gershome
Department of Biomedical Physiology and Kinesiology, TASCII, Simon Fraser University, 8888 University Drive, Burnaby, Canada. Email: cga19@sfu.ca
Online First: January 15, 2015 | Cite this Article
Gershome, C. 2015. Lorcaserin: Making headway. Diabesity 1(1): 11-12. DOI:10.15562/diabesity.2015.9


Obesity is a global problem which has reached epidemic proportions. Obesity is morbidly associated with metabolic syndrome, type-2 diabetes, cardiovascular disease and increased cancer risk. There is an alarming increase in the incidence of obesity in young children which puts them at a greater risk for developing diseases at a much earlier age. Obesity also imposes a heavy burden on the healthcare system. Lorcaserin, a novel anti-obesity drug, is a selective agonist to 5-HT2C receptors thereby reducing food intake and promoting weight loss. Lorcaserin has 15-times and 100-times higher selectivity for the 5-HT2C receptor compared to the 5-HT2A and 5-HT2B receptors, respectively
No Supplementary Material available for this article.
Article Views      : 20
PDF Downloads : 4

Related Articles

Search Authors in












  • Cynthia Gershome

  • Cynthia Gershome

  • Cynthia Gershome